CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that over the next three weeks, it will provide corporate presentations at several investor conferences and host a conference call and webcast to review data presented at the European Hematology Association’s annual meeting.
|Date / Time:||Wednesday, June 4, 2014 at 8:30 AM (EDT)|
|Event:||Jefferies 2014 Global Healthcare Conference|
|Location:||New York City, New York|
|Date / Time:||Tuesday, June 10, 2014 at 4:00 PM (PDT)|
|Event:||Goldman Sachs 35th Annual Global Healthcare Conference|
|Location:||Rancho Palos Verdes, California|
|Date / Time:||Monday, June 16, 2014 at 8:00 AM (EDT)|
|Event:||European Hematology Association (EHA) Conference Call and Data Review|
|Dial-in Information:||877-312-5848 (U.S.); 253-237-1155 (international)|
|Date / Time:||Tuesday, June 17, 2014 at 8:15 AM (EDT)|
|Event:||Wells Fargo Securities 2014 Healthcare Conference|
A live audio webcast of each of these presentations will be available on the “Events and Presentations” page in the Investors & Media section on the Company’s website (http://investor.acceleronpharma.com/events.cfm).
A replay of each of the webcasts will also be available from Acceleron’s website.
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.